|
gptkbp:instance_of
|
gptkb:drug
|
|
gptkbp:bfsLayer
|
6
|
|
gptkbp:bfsParent
|
gptkb:R-CHOP
gptkb:Adriamycin
|
|
gptkbp:activities
|
intercalates DNA
|
|
gptkbp:appointed_by
|
injection
|
|
gptkbp:approves
|
gptkb:FDA
|
|
gptkbp:associated_with
|
peripheral neuropathy
infertility
cognitive impairment
secondary malignancies
radiation recall phenomenon
|
|
gptkbp:brand
|
gptkb:Adriamycin
|
|
gptkbp:can_be_used_with
|
gptkb:paclitaxel
gptkb:cyclophosphamide
gptkb:trastuzumab
|
|
gptkbp:case_types
|
gptkb:healthcare_organization
|
|
gptkbp:class
|
anthracycline
|
|
gptkbp:clinical_trial
|
Phase II
Phase III
Phase I
|
|
gptkbp:contraindication
|
pregnancy
severe liver disease
recent heart attack
|
|
gptkbp:developed_by
|
gptkb:daunorubicin
|
|
gptkbp:discovered_by
|
David L. Longo
|
|
gptkbp:dissolved
|
water-soluble
|
|
gptkbp:dosage_form
|
60-75 mg/m²
|
|
gptkbp:excretion
|
bile
|
|
gptkbp:financial_performance
|
light-sensitive
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Doxorubicin
|
|
gptkbp:influences
|
cell cycle
DNA repair
apoptosis
topoisomerase II activity
|
|
gptkbp:ingredients
|
C27 H29 N O11 S
|
|
gptkbp:is_available_on
|
generic drug
brand name drug
|
|
gptkbp:is_used_for
|
treating cancer
|
|
gptkbp:lifespan
|
20-48 hours
|
|
gptkbp:manager
|
intravenous
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:research
|
combination therapy
pediatric oncology
clinical pharmacology
drug resistance studies
dose optimization
|
|
gptkbp:side_effect
|
nausea
hair loss
cardiotoxicity
myelosuppression
heart damage
extravasation injury
|
|
gptkbp:social_structure
|
anthraquinone
|
|
gptkbp:storage
|
room temperature
|
|
gptkbp:traded_on
|
Doxil
|